Please use this identifier to cite or link to this item:
Title: When should iron chelation therapy be considered in patients with myelodysplasia and other bone marrow failure syndromes with iron overload?
Authors: Forsyth, Cecily J ;Bird, R.;Kenealy, M.;Wellwood, J.;Leahy, M.F.;Seymour, J.F.;To, L.B.
Issue Date: Apr-2012
Source: Volume 42, Issue 4, pp. 450 - 455
Journal title: Internal Medicine Journal
Abstract: Despite the absence of a robust evidence base, there is growing consensus that effective treatment of iron overload leads to decreased morbidity and premature mortality in patients with good prognosis myelodysplastic syndromes (MDSs). Furthermore, new treatment modalities, including disease-modifying therapies (lenalidamide and azacytidine) and reduced intensity conditioning therapies for allogeneic blood stem cell transplants, are offering the prospect of longer survival for patients with traditionally less favourable prognosis MDS, who might also benefit from iron chelation. This article proposes assessment of patients with MDS and related bone marrow failure syndromes to determine suitability for iron chelation. Iron chelation therapy options and monitoring are discussed.
DOI: 10.1111/j.1445-5994.2012.02734.x
ISSN: 1444-0903
Publicaton type: Journal Article
Keywords: Haematology
Appears in Collections:Haematology

Show full item record

Page view(s)

checked on Feb 3, 2023

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.